Longeveron LGVN
Longeveron FY 2023: revenue $709K, down 42%; diluted EPS −$1.02
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001213900-24-017521
- Document
- 10-K
Key figures from this report
These are the numbers Longeveron reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$709K−42% from $1.2M in FY 202210-K income statement, on EDGAR
- Net income−$21.4MAgainst −$18.8M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$1.02Against −$0.90 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$4.9M−53% from $10.5M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$19.0MAgainst −$14.0M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Lipocine LPCN public float $16M, Jun 30, 2025
- Marker Therapeutics MRKR public float $17M, Jun 30, 2025
- CalciMedica CALC public float $16M, Jun 30, 2025
- Ernexa Therapeutics ERNA public float $18M, Jun 30, 2025
- Charlie's Holdings CHUC public float $18M, Jun 30, 2025
